Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) in hepatocellular carcinoma (HCC) compared to glioma patients

被引：0
|
作者：
Raymond, Eric [1 ]
Faivrel, Sandrine [1 ]
Santoro, Armondo [2 ]
Kelley, Robin K. [3 ]
Kelley, Robin K. [3 ]
Merle, Philippe [4 ]
Gane, Ed [5 ]
Douillard, Jean-Yves [6 ]
VValdschmidt, Dirk [7 ]
Mulcahy, Mary [8 ]
Costentin, Charlotte [9 ]
Minguez, Beatriz [10 ]
Di Lena, Luca [11 ]
Gueorguieva, Ivelina [12 ]
Miles, Colin [12 ]
Cleverly, Ann [12 ]
Lahn, Michael M. [12 ]
Ameryckx, Sophie [12 ]
Benhadji, Karim A. [12 ]
Giannelli, Gianluigi [11 ]
机构：
[1] Hop Beaujon, Clichy, France
[2] Humanitas Canc Ctr IRCCS, Milan, Italy
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Hop Croix Rousse, F-69317 Lyon, France
[5] Auckland City Hosp, Auckland, New Zealand
[6] Ctr Rene Gauducheau, St Herblain, France
[7] Univ Klinikum Koln, Cologne, Germany
[8] Northwestern Univ, Chicago, IL 60611 USA
[9] Hop Henri Mondor, F-94010 Creteil, France
[10] Vall dHebron, Liver Unit, Barcelona, Spain
[11] Univ Bari, Bari, Italy
[12] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C261
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C261
引用
收藏
页数：2
相关论文
共 38 条
  • [21] Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate
    Sepulveda-Sanchez, Juan
    Ramos, Ana
    Hilario, Amaya
    De Velascoi, Guillermo
    Castellano, Daniel
    Garcia De La Torre, Marta
    Rodon, Jordi
    Lahn, Michael F.
    ONCOLOGY LETTERS, 2015, 9 (06) : 2442 - 2448
  • [22] Plasma microRNAs associated with overall survival in patients with hepatocellular carcinoma treated with galunisertib (LY2157299 monohydrate), an inhibitor of transforming growth factor-β receptor1
    Estrem, Shawn T.
    Man, Michael
    Zhang, Xuekui
    Nguyen, Duytrac
    Yu, Danni
    Lahn, Michael M.
    Cleverly, Ann
    Desaiah, Durisala
    Faivre, Sandrine
    Gianneli, Gianluigi
    Benhadji, Karim A.
    CANCER RESEARCH, 2016, 76
  • [23] A TGF-B RECEPTOR I KINASE INHIBITOR, GALUNISERTIB (LY2157299) INHIBITS HEPATOCELLULAR CARCINOMA PROGRESSION IN IN VIVO EXPERIMENTAL MODELS
    Buccoliero, C.
    Consolante, D.
    Dituri, F.
    Mancarella, S.
    Hanafy, N.
    Mancinelli, A.
    Trerotoli, P.
    Leporatti, S.
    Pisano, C.
    Giannelli, G.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S565 - S565
  • [24] Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
    Armin Maier
    Anne-Lise Peille
    Vincent Vuaroqueaux
    Michael Lahn
    Cellular Oncology, 2015, 38 : 131 - 144
  • [25] Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
    Maier, Armin
    Peille, Anne-Lise
    Vuaroqueaux, Vincent
    Lahn, Michael
    CELLULAR ONCOLOGY, 2015, 38 (02) : 131 - 144
  • [26] A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP)
    Faivre, Sandrine J.
    Santoro, Armando
    Gane, Edward
    Kelley, Robin Kate
    Hourmand, I. Ivier
    Assenat, Eric
    Gueorguieva, Ivelina
    Cleverly, Ann
    Desaiah, Durisala
    Lahn, Michael M. F.
    Raymond, Eric
    Benhadji, Karim A.
    Giannelli, Gianluigi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
    Bueno, Lorea
    de Alwis, Dinesh P.
    Pitou, Celine
    Yingling, Jonathan
    Lahn, Michael
    Glatt, Sophie
    Troconiz, Inaki F.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 142 - 150
  • [28] PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-ETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA
    Desjardins, Annick
    Suarez, Cristina
    Forsyth, Peter
    Gueorguieva, Ivelina
    Cleverly, Ann
    Burkholder, Tiana
    Desaiah, Durisala
    Lahn, Michael M.
    Guba, Susan C.
    Wick, Wolfgang
    Rodon, Jordi
    NEURO-ONCOLOGY, 2016, 18 : 4 - 4
  • [29] Structural Properties Study and Spectroscopic (FT-IR and UV-Vis) Profiling of the Novel Antagonist LY2157299 as a Transforming Growth Factor-β (TGF-β) Receptor I Kinase Inhibitor by Quantum-mechanical (QM) and Molecular Docking Techniques
    Nabati, Mehdi
    Sabahnoo, Hamideh
    Lohrasbi, Elaheh
    Mazidi, Mohammad
    CHEMICAL METHODOLOGIES, 2019, 3 (03): : 383 - 397
  • [30] Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth
    Wan, Xinhai
    Li, Zhi-Gang
    Yingling, Jonathan M.
    Yang, Jun
    Starbuck, Michael W.
    Ravoori, Murali K.
    Kundra, Vikas
    Vazquez, Elba
    Navone, Nora M.
    BONE, 2012, 50 (03) : 695 - 703
1234